Since tamoxifen-based endocrine therapy is the mainstay of adjuvant therapy for ER+ breast cancer, a major concern with endocrine therapy is the development of acquired resistance in approximately 40% of patients who receive tamoxifen.86 Here, ESR1 is linked to breast cancer.